Antiparasitic therapy
- PMID: 21628620
- PMCID: PMC3104918
- DOI: 10.4065/mcp.2011.0203
Antiparasitic therapy
Abstract
Parasitic diseases affect more than 2 billion people globally and cause substantial morbidity and mortality, particularly among the world's poorest people. This overview focuses on the treatment of the major protozoan and helminth infections in humans. Recent developments in antiparasitic therapy include the expansion of artemisinin-based therapies for malaria, new drugs for soil-transmitted helminths and intestinal protozoa, expansion of the indications for antiparasitic drug treatment in patients with Chagas disease, and the use of combination therapy for leishmaniasis and human African trypanosomiasis.
References
-
- Centers for Disease Control and Prevention (CDC) Guidelines for treatment of malaria in the United States. http://www.cdc.gov/malaria/resources/pdf/treatmenttable.pdf Accessed April 29, 2011
-
- Dondorp A, Nosten F, Stepniewska K, Day N, White N. Artesunate versus quinine for treatment of severe falciparum malaria: a randomised trial. Lancet. 2005;366:717-725 - PubMed
-
- Centers for Disease Control and Prevention (CDC) Notice to readers: new medication for severe malaria available under an investigational new drug protocol. Morb Mortal Wkly Rep. 2007;56(30):769-770 http://www.cdc.gov/Mmwr/preview/mmwrhtml/mm5630a5.htm Accessed April 29, 2011
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
